AXQ Capital LP Purchases New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

AXQ Capital LP acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 22,432 shares of the company’s stock, valued at approximately $39,000.

A number of other large investors have also recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Taysha Gene Therapies in the 4th quarter valued at about $186,000. Privium Fund Management B.V. raised its position in Taysha Gene Therapies by 12.4% during the fourth quarter. Privium Fund Management B.V. now owns 134,900 shares of the company’s stock valued at $233,000 after purchasing an additional 14,900 shares during the period. Cibc World Markets Corp bought a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. Commonwealth Equity Services LLC boosted its holdings in shares of Taysha Gene Therapies by 110.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock worth $102,000 after purchasing an additional 31,000 shares during the period. Finally, E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $31,000. 77.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TSHA has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Up 1.2 %

NASDAQ TSHA opened at $1.66 on Tuesday. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32. The company’s 50-day moving average price is $1.63 and its 200-day moving average price is $1.92. The stock has a market cap of $340.30 million, a PE ratio of 2.63 and a beta of 0.91. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.